Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction

Authors:

Abstract
Patients with heart failure (HF) face a challenging prognosis, with a 50% mortality rate in 5 years. In addition, HF remains a leading cause of hospitalization for adults and costs the US health care system approximately $40 billion per year.1 Over the past 3 decades, therapies that inhibit or alter neurohormonal pathways have led to improvements in morbidity and mortality among patients with HF with reduced ejection fraction (HFrEF).

This publication has 24 references indexed in Scilit: